These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Bell RL; Young PR; Albert D; Lanni C; Summers JB; Brooks DW; Rubin P; Carter GW Int J Immunopharmacol; 1992 Apr; 14(3):505-10. PubMed ID: 1618602 [TBL] [Abstract][Full Text] [Related]
9. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Wenzel SE; Kamada AK Ann Pharmacother; 1996; 30(7-8):858-64. PubMed ID: 8826571 [TBL] [Abstract][Full Text] [Related]
10. Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers. Wong SL; Drajesk J; Chang MS; Witt G; Awni WM Biopharm Drug Dispos; 1998 Apr; 19(3):159-62. PubMed ID: 9569998 [TBL] [Abstract][Full Text] [Related]
11. Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Payne AN; Jackson WP; Salmon JA; Nicholls A; Yeadon M; Garland LG Agents Actions Suppl; 1991; 34():189-99. PubMed ID: 1793063 [TBL] [Abstract][Full Text] [Related]
12. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Watkins PB; Dube LM; Walton-Bowen K; Cameron CM; Kasten LE Drug Saf; 2007; 30(9):805-15. PubMed ID: 17722971 [TBL] [Abstract][Full Text] [Related]
13. New frontiers in asthma therapy: leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Introduction. Hendeles L Pharmacotherapy; 1997; 17(1 Pt 2):1S-2S. PubMed ID: 9017782 [No Abstract] [Full Text] [Related]
14. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Drazen JM; Yandava CN; Dubé L; Szczerback N; Hippensteel R; Pillari A; Israel E; Schork N; Silverman ES; Katz DA; Drajesk J Nat Genet; 1999 Jun; 22(2):168-70. PubMed ID: 10369259 [TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase pathway. Drazen JM; Israel E Int Arch Allergy Immunol; 1995; 107(1-3):319-20. PubMed ID: 7613158 [TBL] [Abstract][Full Text] [Related]
16. Zileuton: a new therapy for asthma or just the first of a new class of drugs. Hendeles L; Marshik PL Ann Pharmacother; 1996; 30(7-8):873-5. PubMed ID: 8826576 [No Abstract] [Full Text] [Related]
17. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor. Shirumalla RK; Sharma P; Dastidar SG; Paliwal JK; Kakar S; Varshney B; Singh Saini G; Sattigeri V; Salman M; Ray A Inflamm Res; 2008 Mar; 57(3):135-43. PubMed ID: 18369577 [TBL] [Abstract][Full Text] [Related]
18. Zileuton use and phenotypic features in asthma. Thalanayar Muthukrishnan P; Nouraie M; Parikh A; Holguin F Pulm Pharmacol Ther; 2020 Feb; 60():101872. PubMed ID: 31841698 [TBL] [Abstract][Full Text] [Related]
19. Lack of cytochrome P450 1A2 interaction effect of ABT-761 on the pharmacokinetics of theophylline. Wong SL; Cavanaugh JH; Qian J; Hansen R; Awni WM Am J Ther; 1998 Sep; 5(5):303-6. PubMed ID: 10099073 [TBL] [Abstract][Full Text] [Related]
20. Safety and clinical efficacy of zileuton in patients with chronic asthma. Lazarus SC; Lee T; Kemp JP; Wenzel S; Dubé LM; Ochs RF; Carpentier PJ; Lancaster JF Am J Manag Care; 1998 Jun; 4(6):841-8. PubMed ID: 10181070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]